This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Cimzia
  • /
  • Multicenter Study Evaluating Certolizumab Pegol Co...
Clinical trial

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

Read time: 1 mins
Last updated:4th Mar 2024
Status: COMPLETED
Identifier: NCT02552212
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)


ClinicalTrials.gov ID: NCT02552212

Sponsor: UCB BIOSCIENCES GmbH
Information provided by: UCB Pharma (UCB BIOSCIENCES GmbH) (Responsible Party)
Last Update Posted: 2022-08-18

Brief Summary:
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients.

Official Title:
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation

Intervention / Treatment:
- Biological: Certolizumab Pegol
- Other: Placebo

Category Value
Study Start (Actual) 2015-09
Primary Completion (Estimated) 2018-05
Study Completion (Estimated) 2020-05
Enrollment (Estimated) 317
Study Type Interventional
Phase Phase 3
Other Study ID Numbers
AS0006

2015-001894-41 (EudraCT Number)


View full details